

CURRICULUM VITAE

1. **Surname:** Enikeev
2. **Name:** Dmitry
3. **Date of Birth** 21.01.1982
4. **Degree:** PhD
5. **Fax:** +7 499 248 51 62
6. **Cell Phone:** +7 925 517 79 26
7. **Email:** dvenikeev@gmail.com

Brief outline.

Urologic surgeon specializing in endourology with a focus on BPH and bladder cancer and urologic oncology with a focus on minimally invasive ablative techniques (Cryo, Brachy, IRE).

- EEP experience > 2000 cases
- En bloc resection of bladder tumor > 500 cases
- Cryoablation of the RCC > 100 cases
- Ablative therapy for prostate cancer (brachytherapy, cryoablation) > 100 cases
- Focal therapy for prostate cancer (irreversible electroporation) > 50 cases

Co-developed a family of thulium fiber lasers which are now widely used for BPH, bladder cancer and kidney stones.

- Board member of the European Association of Urology, Section of Uro-Technology.
- Expert for the Ministry of Science and Higher Education of the Russian Federation.
- Most prolific researcher of Sechenov University 2020.
- Editor for Current Opinion in Urology.
- Editor for Frontiers in Surgery journal (Scopus Q1).

Reviewer for the following journals: World Journal of Urology, British Journal of Urology, Lasers in Surgery and Medicine, Translational Journal of Urology, Asian Journal of Urology, BMC Urology, Andrologia, Research and Reports in Urology, The Lancet.

8. Languages:

Languages	Speaking	Reading	Writing
<i>Russian</i>	native language		
<i>English</i>	5	5	5

9. Work experience:

Occupation	Date (month, year)		Name of the institution, unit or division Address
	from	to	
Head of International Office	12.2021	present	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8
Deputy Director of Biomedical Science & Technology Park	03.2021	11.2021	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8
Professor at the Institute for Urology and Reproductive Health, Sechenov University	03.2021	present	Institute for Urology and Reproductive Health, Sechenov University Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Editorial Board Member	03.2021	present	Journal: Turkish Journal of Urology İstanbul Üniversitesi İstanbul Tıp Fakültesi, Üroloji Anabilim Dalı, İstanbul, Turkey
Editorial Board Member	09.2020	present	Journal: Frontiers of Surgery Avenue du Tribunal Fédéral 34 CH – 1005 Lausanne Switzerland
Editorial Board Member	02.2019	present	Journal: Current Opinion in Urology Citi Building, 41st Floor 25 Canada Square Canary Wharf London E14 5LQ United Kingdom
Board Member	05.2019	present	European Association of Urology Section of Uro-Technology (ESUT) Ablative Group EAU Central Office PO Box 30016NL-6803 AA Arnhem, The Netherlands
Deputy Director for Research	05.2017	present	Institute for Urology and Reproductive Health, Sechenov University Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Associate Professor			Institute for Urology and Reproductive Health, Sechenov University

	12.2016	04.2017	Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Senior Researcher	06.2014	04.2015	Institute for Urology and Reproductive Health, Sechenov University Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Urologist	05.2006	present	Department of Urology, Sechenov University Russia, Moscow, 119991. Trubetskaya str. 8, bld 1

10. Job experience: 15 years

11. Education:

<i>Qualification</i>	<i>Certificate №</i>	<i>Date (month, year)</i>	<i>Name of the institution, unit or division Address</i>
Urology	402406032376	03.2020	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Brachytherapy of prostate cancer	402406032376	03.2020	National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation Obninsk, Korolyova str., 4
Oncology	770400189848	05.2019	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Transfusiology	772404532385	11.2017	Federal state budgetary institution “National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation

			105203, Moscow, Nizhnyaya Pervomayskaya str., 70
Brachytherapy for prostate cancer	772400881739	04.2015	Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology). 117997 Moscow, Profsoyuznaya str., 86,
Ultrasound diagnostics	PP 005682	12.2015	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Radiology	0377060100793	12.2014	Federal state budgetary educational institution of further professional education "Russian Medical Academy of Postgraduate Education" of the Ministry of Health of the Russian Federation Russia, Moscow, 123242 Barricadnaya str. 2/1. bld 1
Oncology	0377060052191	05.2014	Federal state budgetary educational institution of further professional education "Russian Medical Academy of Postgraduate Education" of the Ministry of Health of the Russian Federation Russia, Moscow, 123242 Barricadnaya str. 2/1. bld 1
PhD	097588	12.2009	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8, bld 1

Urology	2942651	08.2006	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8, bld 1
Doctor of Medicine	VSV 0369112	08. 2004	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Russia, Moscow, 119991. Trubetskaya str. 8, bld 1

12. Clinical trials

<i>Number</i>	<i>Field of research</i>	<i>Role</i>	<i>Year</i>	
			<i>From</i>	<i>To</i>
Evaluation of efficacy and safety of Chlorhexidine - Ferein solution for external use 0.5% (CJSC Bryntsalov - A) compared to Chlorhexidine solution for external 0.5% (LLC Rosbio)	Surgery	Co-investigator	2014	2014
Protocol ACHN-490- 009 № 546 (29.09.2015) Randomized, multicenter, multinational, double-blind study comparing the efficacy and safety of plazomicin compared with meropenem followed by optional oral (PO) therapy in the treatment of cUTI, including AP, in adults	Urology, Nephrology	Co-investigator	2015	2017
Protocol D081DC00008 № 665 (25.11.2014) Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and	Oncology	Co-investigator	2014	2020

Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel				
Protocol MK-7902-002-00 № 611 (06.12.2018) Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)	Oncology	Co-investigator	2019	present
NCT03554070 Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP): Efficacy and Safety	Urology	Principal investigator	2018	2020
NCT03504995 Efficacy and Safety Assessment of IRE of Localized Prostate Cancer	Oncology, urology	Principal investigator	2018	2020
NCT03230721 ThuLEP vs. HoLEP vs. Monopolar Enucleation in Management of BPH ThuLEP vs. HoLEP vs. Monopolar Enucleation in Management of BPH	Urology	Principal investigator	2016	2017
NCT04110483 Thulium Fiber Laser En-bloc Resection vs Conventional Transurethral Resection of Non-muscle-invasive Bladder Cancer	Oncology, urology	Principal investigator	2015	2018
03-01_KHAA A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients	Infectious diseases	Principal investigator	2020	present

with COVID-19 Infection.				
MK 6482-005 An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies	Oncology, urology	Principal investigator	2020	present
CA2097DX A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivolumAB clinical Trial Evaluation 7DX)	Oncology, urology	Co-investigator	2021	present
56021927PCR3015 A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational	Oncology, urology	Co-investigator	2021	present
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder	Oncology, urology	Principal investigator	2021	present

Cancer (KEYNOTE-905/EV-303)				
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)	Oncology, urology	Principal investigator	2021	present
A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations Protocol 42756493BLC3001	Oncology, urology	Co-investigator	2021	Present
A Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib combined with Isoquercetin, and Best Supportive Care in Hospitalized Patients with Moderate and Severe COVID-19 (AB20001)	Infectious diseases	Principal investigator	2021	Present

13. GCP certificates


Name	Date <i>Month, year</i>		<i>Name of the institution Unit (division) Address</i>
	from	to	
Principles and practice of clinical research	11.2011	11.2011	The National Institutes of Health Clinical Center
Principles of ICH-GCP	10.2020	10.2020	Pfizer Investigator Training Program

13. Number of articles (Scopus) – 168

14. [Scopus Author ID: 25027418800](#)

15. H-index - 13

Signature



Date

13 Apr 2022